Advanz Looks To Nix Regeneron, Bayer Eye Med Patents
Pharmaceutical company Advanz has asked a London court to revoke a number of U.K. eye medicine patents belonging to Regeneron and Bayer, arguing that the treatments are not inventive enough....To view the full article, register now.
Already a subscriber? Click here to view full article